Adebrelimab for advanced small cell lung cancer in routine care
Official title: A Real-world Study on the Efficacy and Safety of Adebrelimab in the Treatment of Advanced-stage Small Cell Lung Cancer
Run by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · NCT07434518 · Data updated 2026-11-12
This project will try adebrelimab, a PD-L1 blocker, in adults with extensive-stage small cell lung cancer to see how safe it is and how well it controls the disease in routine clinical care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Academic / other |
| Drugs / interventions | adebrelimab |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | January 27, 2026 |
| Main results expected | December 31, 2027 |
| Study ends | June 30, 2028 |
| Registry record updated | February 25, 2026 |
| Trial ID | NCT07434518 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with histologically or cytologically confirmed extensive-stage small cell lung cancer who are judged by their physician to be eligible for or already receiving adebrelimab are ideal candidates.
✕Probably not a fit
Patients receiving other immune-modulating therapies, enrolled in other interventional trials, with concurrent other malignancies, or lacking key clinical data are unlikely to participate or benefit from this observational program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational real-world study follows adults with extensive-stage small cell lung cancer who are eligible for or already receiving adebrelimab, collecting safety and outcome data without altering planned treatment. Safety monitoring focuses on immune-related adverse events, particularly grade ≥3 events, from the first dose until 90 days after the last dose, while efficacy endpoints include overall survival, progression-free survival, objective response rate, and disease control rate. The study will also explore how baseline factors such as brain or liver metastases and biomarker status relate to prognosis. Data are collected at several hospitals in Shanghai as part of routine clinical practice.
Why it matters
Potential benefit: If successful, the study could confirm adebrelimab's safety and real-world effectiveness and help clinicians use it more confidently for extensive-stage SCLC.
How similar studies have gone: Other PD-1/PD-L1 agents have shown survival benefit when added to chemotherapy in extensive-stage SCLC, so this study builds on class-level successes though adebrelimab-specific real-world evidence remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically or cytologically confirmed extensive-stage small cell lung cancer; * Age ≥ 18 years; * The investigator determines that the patient is eligible for or is already receiving adebrelimab treatment. Exclusion Criteria: * Patients concurrently receiving other immune-modulating drugs or therapies; * Patients currently participating in other interventional studies; * Patients with concurrent other malignancies; * Patients with missing key study-related data.
Where it's running
-
Shanghai General Hospital
Shanghai, China Recruiting
Study contacts
- Study coordinator: Qingnan Zhao, PhD
- Email: zhaoqingnan2010@126.com
- Phone: +86 (021)37798597
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Propranolol with Adebrelimab and Platinum Chemotherapy in Small Cell Lung Cancer
This early-phase trial tests whether adding propranolol to adebrelimab plus platinum chemotherapy is safe and may help treat small cell lung cancer in adults.
-
Multiomic analysis in relapsed small-cell lung cancer with DLL3 T cell engager
This observational study tests how blood and tumor markers change over time in adults with relapsed small-cell lung cancer who are receiving a DLL3-targeted therapy, to see if those changes relate to clinical outcomes.
-
Using Adebrelimab with chemotherapy for early-stage small cell lung cancer
This study is testing if adding Adebrelimab to chemotherapy helps people with early-stage small cell lung cancer do better before surgery compared to just chemotherapy alone.
-
68Ga-YQ-CC05: a new probe for detecting tumors with CCK2R
This study tests a radioactive probe called 68Ga-YQ-CC05 to see if it can safely help find tumors in adults with certain cancers using PET-CT imaging.
-
Exploration of whole-brain radiotherapy with PD-1 inhibitors for brain injury in SCLC
This study tests whether adding PD-1 inhibitors to chemotherapy and prophylactic brain irradiation helps some small cell lung cancer patients protect the brain.
-
IDP-121 plus chemotherapy in platinum-resistant small cell lung cancer
This trial tests higher and higher doses of IDP-121 with chemotherapy to see if it is safe and workable for adults with advanced small cell lung cancer that progressed after first-line platinum therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.